Quantcast

Latest diabetic neuropathy Stories

2011-04-13 21:52:53

Compounds helped nerve extensions re-grow faster in mouse studies Drugs already in development to treat Alzheimer's disease may eventually be tapped for a different purpose altogether: re-growing the ends of injured nerves to relieve pain and paralysis. According to a new Johns Hopkins study, experimental compounds originally designed to combat a protein that builds up in Alzheimer's-addled brains appear to make crushed or cut nerve endings grow back significantly faster, a potential boon for...

2011-04-12 08:07:52

(Ivanhoe Newswire) -- The American Academy of Neurology has issued a new guideline on the most effective treatments for diabetic nerve pain -- the burning or tingling pain in the hands and feet that affects millions of people with diabetes. Diabetic nerve pain, or neuropathy, is caused by nerve damage. "When neuropathy strikes, it is painful and can disrupt sleep; because of this, it can also lead to mood changes and lower quality of life," lead guideline author Vera Bril, MD, FRCP, with the...

2011-02-15 07:00:00

BRIDGEWATER, N.J. and TORONTO, Feb. 15, 2011 /PRNewswire/ -- Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) and Sunnybrook Health Sciences Centre (Toronto, Canada) announced that they have entered into a research agreement and licensing option for vasculotide, an investigational compound to treat chronic wounds. This includes neuropathic diabetic foot ulcers caused by a lack of sensation and neuropathic ulcers that are complicated by peripheral arterial disease, commonly called neuroischemic...

2011-02-08 00:11:45

Gilad&Gilad LLC of Reseda (Los Angeles), California, has re-launched Neurofencine(TM), a first-of-its-kind nutraceutical supplement clinically proven for nerve resilience and pain-free nerve functions. Neurofencine(TM) targets unmet needs of millions of people who cope with circumstances affecting normal nerve functions. Reseda, CA (PRWEB) February 6, 2011 Neurofencine(TM) development is the outcome of breakthrough discoveries made and patented by the neuroscientist founders of...

2011-02-02 15:00:00

RICHMOND, Calif., Feb. 2, 2011 /PRNewswire/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) today reported fourth quarter and full year 2010 financial results and accomplishments. For the fourth quarter ended December 31, 2010, Sangamo reported a consolidated net loss of $8.3 million, or $0.18 per share, compared to a net loss of $2.4 million, or $0.05 per share, for the same period in 2009. As of December 31, 2010, the company had cash, cash equivalents, marketable securities and interest...

2011-01-27 14:41:20

Researchers have proved that a single "master switch" enzyme, known as aldose reductase, is key in producing excess mucous that clogs the airways of people with asthma and chronic obstructive pulmonary disease (COPD). The enzyme's action can be blocked by drugs whose safety has been shown in clinical trials for other diseases "“ a discovery that could improve therapies for the 510 million people worldwide suffering from asthma and COPD. The findings are from a University of Texas...

2011-01-10 06:00:00

RICHMOND, Calif., Jan. 10, 2011 /PRNewswire/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced today that the company completed enrollment of its Phase 2b double-blind, placebo-controlled clinical trial (SB-509-901) in subjects with diabetic neuropathy (DN). The company expects to have efficacy data from this study in the second half of 2011. The company also plans to present the first human clinical data from its Phase 1 trials of SB-728-T in HIV/AIDS in the first quarter of 2011....

2010-11-17 15:00:00

RICHMOND, Calif., Nov. 17, 2010 /PRNewswire-FirstCall/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced today the presentation of Phase 2 clinical data from its ZFP Therapeutic program to develop SB-509, a zinc finger protein transcriptional activator (ZFP-TF) of the vascular endothelial growth factor (VEGF)-A gene as a treatment for ALS. The data from study SB-509-801 demonstrated that the drug was well-tolerated in subjects with ALS and that 40% of SB-509 treated subjects had...

2010-11-03 00:00:35

Alpha lipoic acid is a remarkable natural substance, with surprisingly diverse and beneficial properties, but diminished by the poor solubility of raw material crystalline alpha lipoic acid powder used in most oral formulations. The 10th anniversary of the ground-breaking discovery of a high-bioavailability solubilized formulation is being celebrated with a free bottle offer of ThioGel solubilized alpha lipoic acid softgel capsules. Wyckoff, NJ (PRWEB) November 2, 2010 Alpha lipoic acid is...

2010-09-14 08:03:00

BALTIMORE, Sept. 14 /PRNewswire/ -- Arcion Therapeutics, a venture backed clinical stage biotechnology company developing topical therapies for chronic pain, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to ARC-4558 for the treatment of pain associated with Painful Diabetic Neuropathy (PDN). ARC-4558 is a 0.1% gel formulation of clonidine hydrochloride for topical administration. Arcion recently announced positive top-line results from a...


Word of the Day
humgruffin
  • A terrible or repulsive person.
Regarding the etymology of 'humgruffin,' the OED says (rather unhelpfully) that it's a 'made-up word.' We might guess that 'hum' comes from 'humbug' or possibly 'hum' meaning 'a disagreeable smell,' while 'gruffin' could be a combination of 'gruff' and 'griffin.'